Long-Term Tetrahydrobiopterin Treatment in PKU Patients of 0-18 Years - Study on Phenylalanine Tolerance and Safety
Double-Blind, Placebo Controlled, Multicentre Study With an Open Label Extension to Evaluate the Efficacy and Safety of Tetrahydrobiopterin (BH4) in Children and Adolescents With Hyperphenylalaninemia Caused by Phenylalanine Hydroxylase Deficiency
PhasePhase 2/Phase 3
Lead SponsorOrphanetics Pharma Entwicklungs GmbH
Indication/ConditionPhenylalanine Hydroxylase Deficiencies
The aim of the study is to confirm the efficacy and safety of BH4 in the treatment of hyperphenylalaninemia caused by phenylalanine hydroxylase deficiency in patients responsive to BH4. The primary objective is to assess the effect of BH4 on phenylalanine tolerance compared to placebo under optimal blood phenylalanine control and to demonstrate safety in 12 months long-term treatment. Additionally population PK will be assessed.
Inclusion Criteria: Female and male patients, aged 0-18 years Phenylalanine-4-hydroxylase (PAH) deficiency shown by mutation analysis Blood phenylalanine concentration in the target range under dietary treatment Written consent of a parent or legal representative Assumed availability within the period of study participation Patients/parents willing and able to follow the recommended diet Use of an effective method of contraception in female patients of child bearing potential Exclusion Criteria: BH4-deficiency due to genetic disorders in biosynthesis or recycling of BH4 History or current evidence of poor diet compliance History or current evidence of clinically relevant allergic or idiosyncratic reactions to drugs or food History of allergic reactions to BH4 or its excipients Positive pregnancy test (ß-HCG in serum) and lactating females Participation in other drug trials within the last 30 days before start for the study